EC9706-luc Orthotopic Mouse Model Service for Esophageal Cancer

EC9706-luc Orthotopic Mouse Model Service for Esophageal Cancer provides a luciferase-tagged, organ-site-matched xenograft system in which human esophageal squamous cell carcinoma grows in the mouse esophagus and can be tracked non-invasively in real time. Backed by experienced surgical teams and imaging-based study management, Alfa Cytology delivers this model end-to-end—from verified luciferase-expressing cell preparation and orthotopic implantation to serial bioluminescence monitoring and terminal histopathology—so your preclinical candidates are tested in a setting that genuinely resembles the human tumor niche.

Overview of EC9706-luc Orthotopic Mouse Model for Esophageal Cancer

EC9706 is a long-established human esophageal squamous cell carcinoma (ESCC) line derived from a resected tumor specimen, characterized by a 26-hour generation time, a colony-forming efficiency above 90%, robust anchorage-independent growth, and strong tumorigenicity in nude mice. The EC9706-luc derivative stably expresses firefly luciferase, which converts tumor mass into a quantifiable light signal after D-luciferin administration. When these labeled cells are injected into the intraesophageal wall of immunodeficient mice, tumors establish at the native organ site and their growth kinetics can be followed weekly by bioluminescence imaging without repeated palpation or interim sacrifice.

Fig 1. Histopathological characterization of spontaneous multiorgan metastasis in an EC9706-derived esophageal squamous cell carcinoma model, demonstrating metastatic dissemination to the liver, lung, heart, pancreas, spleen, and kidney. (Gao, Pan, et al., 2021)

This orthotopic, imaging-enabled configuration captures disease features that flank xenografts miss, including nodular intraluminal growth with esophageal stricture, invasion through the esophageal wall layers, lymphovascular involvement, and perineural infiltration—features documented for luciferase-labeled ESCC orthotopic systems. Because signal intensity correlates with tumor burden, treatment effects can be measured longitudinally in the same animal, reducing cohort size while increasing statistical resolution. The result is a versatile platform suited to gene-function studies, metastasis observation, and therapeutic regimen testing in preclinical esophageal cancer research.

Cell Line Information: EC9706-luc

The parental EC9706 line was established from an ESCC specimen and has served ESCC research for more than two decades; EC9706-luc is its firefly luciferase–expressing derivative, generated by stable transduction so that tumor cells emit a photon signal upon substrate administration. One caution documented for this line is cross-contamination with HeLa cells in some distributed stocks, which is why ICLAC registration and pre-study authentication are essential. The principal attributes are listed below.

Our Services

Working with Alfa Cytology means the EC9706-luc orthotopic model is treated as an integrated system rather than a one-time surgical procedure: reporter expression is verified before implantation, imaging schedules are built around your dosing calendar, and every data package is reviewed for biological consistency before release. Whether you need a pilot feasibility run or a multi-arm efficacy study, the team aligns the model parameters with your mechanism of interest and keeps the program firmly within preclinical boundaries.

Workflow of EC9706-luc Orthotopic Mouse Model Construction

Building a reliable EC9706-luc orthotopic model requires coordination between cell engineering, microsurgery, and imaging. The process below reflects how a typical study proceeds, with a quality gate at each transition:

1. Reporter verification and cell banking: Luciferase expression is confirmed by in vitro bioluminescence readout, and cells are STR-authenticated, mycoplasma-tested, and expanded to a qualified working bank.
2. Inoculum formulation: Cells are harvested at log phase, counted and viability-checked, then resuspended—typically with a basement membrane matrix—at a defined density (frequently around 1 × 10⁶ cells per site).
3. Anesthesia and surgical access: Nude mice are anesthetized and positioned for cervical or abdominal access to the esophagus, with analgesia and sterile technique applied throughout.
4. Intraesophageal wall implantation: The EC9706-luc cell suspension is injected carefully into the esophageal wall near the mid-esophageal region, and the incision is closed to secure the inoculum in place.
5. Recovery and welfare monitoring: Mice are returned to heated recovery cages; body weight, grooming, and feeding behavior are checked daily until normal activity resumes.
6. Bioluminescence baseline and serial imaging: After intraperitoneal D-luciferin injection, an initial IVIS scan establishes baseline signal; weekly imaging thereafter tracks tumor establishment and growth longitudinally.
7. Treatment randomization and dosing: Once signal reaches a pre-specified range, animals are randomized into vehicle and treatment arms, and the test regimen is administered on schedule.
8. Endpoint collection and analysis: At study end, tumors are excised for caliper measurement, H&E histology, and IHC or molecular assays, and imaging data are compiled into a final report.

Fig 2. EC9706-luc orthotopic mouse model construction workflow.

Case Study-EC9706-luc Orthotopic Mouse Model Development

Alfa Cytology has applied luciferase-labeled orthotopic esophageal cancer models in client-sponsored preclinical programs that required sensitive, non-invasive readouts of tumor response over time. These studies covered model establishment, imaging calibration, and treatment arms evaluated by serial bioluminescence followed by histopathological confirmation. Detailed case material can be provided on request once a confidentiality framework is in place, giving your team concrete reference points for feasibility and study planning.

Why Choose Alfa Cytology?

An orthotopic luciferase model succeeds or fails on small details—reporter stability, surgical consistency, and imaging discipline. Here is what Alfa Cytology brings to the EC9706-luc program specifically:

• Verified luciferase performance is confirmed both before and after implantation, so imaging data reflect real tumor biology.
• Microsurgical implantation into the esophageal wall is performed by an experienced team focused on reproducible tumor take.
• Scheduled IVIS acquisition with standardized luciferin dosing delivers comparable signal measurements across time points.
• Study timelines accommodate your dosing scheme, with randomization triggered by quantified tumor burden rather than guesswork.
• Terminal packages integrate imaging curves, gross pathology, H&E, and IHC in one traceable dataset.
• A preclinical-only mandate means every protocol decision is optimized for early research questions, not clinical translation claims.

Contact Us

To explore whether the EC9706-luc orthotopic mouse model fits your esophageal cancer program, contact us today with your study goals and compound profile. The Alfa Cytology team will reply promptly with feasibility input, a proposed timeline, and a customized quotation to help you move from concept to data with confidence.

For research use only. Not intended for any clinical use.